Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.

Stock Information for Profound Medical Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profound Medical Corp.

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
The Quiet Rule Change Tilting $10B Toward Medtech's Most Validated Platforms
Ventripoint Issue Shares for Payment of Debenture Interest
Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
The Quiet Shift Replacing Million-Dollar Heart Scanners With Software
Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group
MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.